XML 71 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Arrangements (Tables)
 12 Months Ended
Dec. 31, 2023
Collaborative Arrangements [Abstract]  
Collaborative Arrangements
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202320222021
Alliance revenue - Lynparza$1,199 $1,116 $989 
Alliance revenue - Koselugo97 54 29 
Total alliance revenue$1,296 $1,170 $1,018 
Cost of sales (1)
311 492 167 
Selling, general and administrative192 185 178 
Research and development79 106 120 
December 3120232022
Receivables from AstraZeneca included in Other current assets
$341 $303 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
256 123 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 600 
(1)    Represents amortization of capitalized milestone payments. Amount in 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202320222021
Alliance revenue - Lenvima$960 $876 $704 
Cost of sales (1)
381 212 195 
Selling, general and administrative189 158 127 
Research and development66 136 173 
December 3120232022
Receivables from Eisai included in Other current assets
$226 $214 
Payables to Eisai included in Accrued and other current liabilities (2)
125 — 
(1)     Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above.
(2)     Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202320222021
Alliance revenue - Adempas/Verquvo$367 $341 $342 
Net sales of Adempas recorded by Merck255 238 252 
Net sales of Verquvo recorded by Merck36 22 7 
Total sales$658 $601 $601 
Cost of sales (1)
224 210 424 
Selling, general and administrative131 153 126 
Research and development90 75 53 
December 3120232022
Receivables from Bayer included in Other current assets
$156 $143 
Payables to Bayer included in Accrued and other current liabilities
80 80 
(1)    Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202320222021
Net sales of Lagevrio recorded by Merck
$1,428 $5,684 $952 
Cost of sales (1)
852 3,038 502 
Selling, general and administrative
97 147 37 
Research and development
60 88 137 
December 3120232022
Payables to Ridgeback included in Accrued and other current liabilities (2)
$113 $348 
(1)    Includes royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Years Ended December 3120232022
Selling, general and administrative
$5 $— 
Research and development (1)
218 288 
December 3120232022
Payables to Moderna included in Accrued and other current liabilities
$63 $7 
(1)    Expenses in 2022 include the $250 million option payment noted above.